ReviewActa pharmacologica Sinica2026
BioPROTACs: a promising approach for targeted protein degradation.
Review in Acta pharmacologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Targeted protein degradation (TPD) has emerged as an important therapeutic strategy in recent years. Proteolysis-targeting chimeras (PROTACs) are among the most extensively studied TPD technologies that eliminate target proteins through a "degradation rather than inhibition" mechanism. This mechanism offers opportunities to target proteins that are difficult to modulate using conventional small-molecule inhibitors and may also help mitigate drug resistance. However, the development of small-molecule PROTACs remains constrained by challenges associated with druggability, target accessibility, E3 ubiquitin ligase availability, and clinical translation. BioPROTACs have subsequently emerged as an alternative degradation platform in which genetically encoded protein modules replace conventional small-molecule ligands while preserving the underlying degradation mechanism. Their molecular design enables broader target recognition, flexible E3 ligase recruitment, and improved molecular specificity. Their emerging applications span cancer, viral infections, and neurodegenerative diseases. This review summarizes the molecular mechanisms, recent advances, and emerging applications of bioPROTAC technology, evaluates the current technical challenges, discusses potential strategies to address these limitations, and highlights future directions that may facilitate its clinical translation.
Indexed as
Identifiers
42687006What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.